a * *JECFA ADI - 2 -
|
|
|
- とき きちや
- 7 years ago
- Views:
Transcription
1 5-10 ADI 5-10 a b c a Letter to Editor d b b a a Table % % * Table mg/kg 12 32% 60 62% * a % 20% 25 BALB/cAJcl 40% 55 C3H/HeNJcl-MTV mg/kg 12 32% 60 62%
2 a * *JECFA ADI - 2 -
3 a mg/kg (1970) 2 / 50% 8-10g 15-20g 5 (%) 0 mg/kg mg/kg mg/kg mg/kg mg/kg / 8-10g 2.5 (%) mg/kg / b g (1969) 4 mg/kg (1,000 RU/mg) 80 mg/kg (50 RU/mg) c mg/kg (1965) / g 0% 40% 50% (8-25g?) JECFA (1968) [2-4] FDA (1984) [2-11] a (1970) b (1969) c (1965) EU (SCF) (1990) 2 3 No adverse effects were (1982) [2-13-a] observed.
4
5
6
7
8
9
10
11
12 A. PubMED NLM PubMED 23 Search Most Recent Queries Result #1 Search mortality Field: All Fields #2 Search mouse Field: All Fields #3 Search sensitivity or susceptibility Field: Title/Abstract #4 Search aging/physiology Field: MeSH Terms #5 Search #1 AND #2 AND #3 AND # Clin Diagn Lab Immunol Sep;8(5): Effects of calorie restriction on polymicrobial peritonitis induced by cecum ligation and puncture in young C57BL/6 mice. 7. J Biol Chem Aug 3;276(31): Epub 2001 May 29. Age-associated differences in cardiovascular inflammatory gene induction during endotoxic stress LPS 8. J Immunol Sep 1;163(5): Role of IL-10 in a neonatal mouse listeriosis model. IL-10 1
13 12. Scand J Immunol Nov;46(5): Increased mortality and impaired clonal deletion after staphylococcal enterotoxin B injection in old mice: relation to cytokines and nitric oxide production. B IFN- FAS TNF- 13 Exp Anim Jul;46(3): Age-related changes in susceptibility of mice to low-virulent mouse hepatitis virus (MHV-2-CC) infection Mech Ageing Dev Feb;73(2): Differences between young and aged mice in susceptibility to Friend virus. Freined Virus, FV 18. J Infect Dis Aug;168(2): Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune response and increased susceptibility of old mice to influenza infection T 22. J Nutr Oct;117(10): Toxicity of palmitoyl glycerol to mice: hypothermia and reversal of the toxicity. rac-1(3)-palmitoyl glycerol Palmitoyl glycerol 6 28 palmitoyl glycerol palmitoyl glycerol 2
14 23. J Immunol Jun 15;138(12): Aging and immunity to tuberculosis: increased susceptibility of old mice reflects a decreased capacity to generate mediator T lymphocytes T
15 B. DIALOG 1 DIALOG 7 MEDLINE EMBASE ToxFile BIOSIS PREVIEWS FOODLINE FSTA JICST Set Items Description S MOUSE OR MICE S SUSCEPTIBILITY OR SENSITIVITY S AGE OR AGING S MORTALITY S6 423 S1 AND S2 AND S4 AND S5 S7 20 S6 AND ORAL S8 15 RD S7 (unique items) Japanese journal of experimental medicine 1975, 45 (4) p Pathogenicity of mouse hepatitis virus for mice depending upon host age and route of infection. day-old Journal of Comparative Pathology ( J. COMP. PATHOL. 2004, 130/1 (58-65) Neurotropism of swine haemagglutinating encephalomyelitis virus (coronavirus) in mice depending upon host age and route of infection
16 8. Experimental Lung Research ( EXP. LUNG RES. ) (United States) 1993, 19/3 ( ) Factors that influence the suppression of pulmonary antibacterial defenses in mice exposed to ozone Streptococcus zooepidemicus ppm 20 PGE 2 5
17 C. DIALOG 2 biopreservatives antibiotics mortality Set Items Description S MOUSE OR MICE S SUSCEPTIBILITY OR SENSITIVITY S AGE OR AGING S BIOPRESERVATIVE? OR ANTIBIOTIC? S5 59 S1 AND S2 AND S3 AND S4 S6 42 RD S5 (unique items) S7 9 S6 AND ORAL 2 3. Infection and immunity (UNITED STATES) Jan 1982, 35 (1) p222-8, Effects of compromising agents on candidosis in mice with persistent infections initiated in infancy. Candida albicans Antibiotiki (USSR) Oct 1976, 21 (10) p [Dependence of the toxicity of the antineoplastic antibiotics rubomycin and carminomycin, on the age and sex of white mice and rats] Karminomycin Karminomycin stable Karminomycin 2 23 Karminomycin Rubomycin LD 50 6
18 2004/8/26 NISIN EDI mg/ / 1 1 non-standardised kg mg/kg / EU EDI *1 EDI TMDI Theoretical Mazimum Daily Intakes *2 p Federal Register 53 FR 11247, Apr. 6, 1988, Food and Drug Administration, HHS DANISCO CONFIDENTIAL NISIN Feb Agency Response Letter GRAS Notice No.GRN Danisco 5 Official Journal of the European Communities 1995 L Volume 2-12
求人面接資料PPT
Hair Salon TV etc. 250" 250" 200" 200" 150" 150" 100" 100" 50" 50" 0" 0" Nov)13" Dec)13" Jan)14" Feb)14" Mar)14" Apr)14" May)14" Jun)14" Jul)14" Dec)12" Jan)13" Feb)13" Mar)13" Apr)13"
初めに：
2 Copyrightc2008 JETRO. All rights reserved. FAX 03-5572-7044 ...5...6 (1)...7... 11... 11...12...14...15...15...16...17...18 (4)...21 (5)...21 (6)...23 4 Copyrightc2008 JETRO. All rights reserved. 5 Copyrightc2008
極地研 no174.indd
C O N T E N T S 02 10 13 no.174 June.2005 TOPICS06 1 45 46 3 12 4546 47 14 10 15 15 16 NEWS no.174 june.2005 0 100 200 300 400 500 600 700 100 100 Diameter,nm 10 10 45 20042 Feb Mar Apr May Jun Jul Aug
本文
Apr 11, 213 (3-3497-3675) miwa-y @itochu.co.jp (3-3497-6284) maruyama-yo @itochu.co.jp 1. (1) (2) (3 (4) 2. (1)3 (2) (3)J (4) (5) (6) (7) (8) (9) (1) 46 3. Summary 2 2% 2 13 13 13 J 79 46 13 46 4 34 2%
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
_2009MAR.ren
ISSN 0389-5254 2009 No.2 MAR JAPAN AIRCRAFT PILOT ASSOCIATION C O N T E N T S No.313 2009 No.2 MAR é 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR
contents
3 3 4 5 6 7 7 8 8 9 9 10 10 10 11 11 12 13 13 14 14 14 14 14 14 contents 3 3 4 5 6 7 7 8 8 9 9 10 10 10 11 11 12 13 13 14 14 14 14 14 14 01 1 22 3 3 44 studies 1 2 Hiroshima Univ. ACTIVITIES campus
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
欧州に見るマイナス金利が銀行に及ぼす影響
TEL 3-6733-17 E-mail 1 / 14 216 5 27 TEL 3-6733-17 E-mail 2 / 14 EU 2161 2146 2152 2127 2149 21412 2163 216 3.1%.1%...5%.6% 1.25%.65% CD.75%.5% 1.45% 1.2% 1 (2164 ).82%.97%.62%.51%.259% 3.325% 2161 1 6,4
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
untitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
請求記号：DVD 70- -1 栄光のフィレンツェ・ルネサンス １ 夜明け 55分
DVD 291- -482 64 DVD 520- -434 170 DVD 520- -435 173 DVD 520- -436 178 DVD 520- -437 94 DVD 520- -438 183 DVD 602.164- -508 38 DVD 70- -1 55 DVD 70- -2 55 DVD 70- -3 55 DVD 70- -4 55 DVD 70- -5 55 DVD
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
PubMedとは
7 1 PubMed 1994 4 1999 4 2004 4 7 PubMed PubMed http://www.ncbi.nlm.nih.gov/pubmed/ http://pubmed.gov National Library of Medicine; NLM PubMed NLM MEDLINE MEDLINE Index Medicus PubMed PubMed 1879 1964
CHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
Fig. 2 Body weight curves rats treated orally with DL-8280 for 4 weeks
Fig. 1 Chemical structure DL-8280 Fig. 2 Body weight curves rats treated orally with DL-8280 for 4 weeks Fig. 3 Food consumption in rats treated orally with DL-8280 for 4 weeks Fig. 4 Water consumption
有明海・八代海総合調査評価委員会 委員会報告書 別添資料
(10 6 m 3 ) 30 20 10 0 S30 S40 S50 S60 H7 260m 3 (7.7) 2,490m 3 (72.9) 500m 3 (14.7) 160m 3 (4.7) COD T-N T-P SS St.7( ) St.9( ) St.1( ) St.7( ) + St.9( ) ( ) ( ) A-2( ) B-2( ) B-3( ) COD T-N T-P SS St.1(
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
VOL. 36 S-3 CHEMOTHERAPY 437
VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
PBO 2000~ PBO Funded Ratio - 12/31/93 to Present 140% 130% 120% 110% 100% 90% 82.6% as of 7/31/ % 70% 81.6% as of YE % 1993
2004 PBO 2000~2002 3 10 1990 PBO Funded Ratio - 12/31/93 to Present 140% 130% 120% 110% 100% 90% 82.6% as of 7/31/2004 80% 70% 81.6% as of YE 1993 60% 199312 199412 199512 199612 199712 199812 199912 200012
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-
PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information
EBM Reviews Ovid Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Revie
EBM Reviews 2006 4 Ovid http://www.usaco.co.jp/products/ovid/ovidplatform.html Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Reviews CDSR Database of Abstracts of Reviews of Effectiveness
Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Jan. 1987 Jan. 1987 THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
untitled
249 1 5 2 (fiscal cliff) 20131 2012 CBO20132.90.5 201350 1200 1171 1000 800 612 600 400 387 200 213 213 186 123 130 142 144 79 0 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 20125 201310 3 88.18.3
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Table 1. Influence of food deprivation on gastric secretion and severity of ulceration in 18 hr pylorus ligated rats.
Table 1. Influence of food deprivation on gastric secretion and severity of ulceration in 18 hr pylorus ligated rats. Fig. 1. Effects of repeated administrations of several mild antiulcer agents on severity
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
DIALOG MEDLINE...1 BIOSIS PREVIEWS...7 DIOGENES: ADVERSE DRUG EVENTS DATABASE PHARMAPROJECTS...21 IMS R&D FOCUS...22 DATASTAR..
DIALOG 200304200403 MEDLINE...1 BIOSIS PREVIEWS...7 DIOGENES: ADVERSE DRUG EVENTS DATABASE...9...15 PHARMAPROJECTS...21 IMS R&D FOCUS...22 DATASTAR...23 http://database.g-search.or.jp 108-0022 Loop-X F
第33回 ESRI－経済政策フォーラム
?! BNP 2.4 2.4 1.6 (1.62).8 (1.56) 1.5 (2.).1.1.2 (.27).4 (.56).3 (.54) 1.9 2.4 2.1.9 1.2 -.1.1..6.2 3.1 2.9 2.2.9 (1.58) 1.4 (2.42) 2.2 2.5 2.3 2.4 1.7 1.6 2.9 2.6 1.1 1.3 1.4 1.4 1.9 1.8 1.9 1 7 65 (PMI)
2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
untitled
Visitor Arrivals and Japanese Overseas Travelers 2008 Visitor Arrivals and Japanese Overseas Travelers Visitor Arrivals by Nationality & Purpose of Visit for Apr. 2008provisional figures Visitor Arrivals
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
福光 寛 １‐３７／１‐３７
April 3, 1999 1999, 37 1999, 38 1999, 38 2004, 70 2004, 69 1998b, 37 1998b, 38-39 1998b, 43 1998b, 40 (1998b) (1999) (1999) (2006) 2006, 19 (2002) (2006) (2006) (2006) http://www.cae.org Released in Feb.
AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urol
AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urology, Kumamoto University College of Medicine (Director:
AAS48.indd
Suzuki K. (2016). Breeding for disease resistance to Mycoplasma pneumonia of swine All about SWINE 48, 2-12 PRDC ARMPS PRRS 18 1 21 24 32 40 MPS EU 2006 2011 SPF 2 3 MPS 5 MPS 4 MPS MPS MPS 2 MPS MPS MPS
ミニレビュー
Molecular mechanisms of the suppression of inflammation by thermal stress Ryosuke Takii Department of Biochemistry and Molecular Biology, Yamaguchi University Graduate School of Medicine, Ube 755-8505,
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
62 No.11
Newsletter of the Tottori Prefectural Museum MARCH No. 11 62 No.11 No.11 73 4 No.11 No.11 5 62 No.11 No.11 73 INFORMATION LECTURE FIELD STUDY SATURDAY ART FEVER 4 ARL. 5 MAY. 6 JUN. 7 JUL. MUSEUM PRESS
1 2 D- D- 1206 D- D- -2003 120 /2004 D-FDA GRAS D D- 3 5 5 D- 75 10g/kg 14 40 20 D-101520 90 1520 20%101520 1520 D- 5(D- 2300-6700mg//) () 2024 615 D- 41220g/kg/ 1220g/kg/ 20g/kg/ 1220g/kg/ () 50 D- 10%
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL http://hdl.handle.net/10130/526 Right Posted at the Institutional Resources for Unique Colle Available from
VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3
VOL. 20 NO. 5 CHEMOTHERAPY 653 2-Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3376, SDM, SIZ and SMZ against Gram-positive and negative
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
CHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
Regular Midgrade Premium Total Conventional 451 43 68 562 66.6% 56.6% 58.1% 64.6% Oxygenated 22 4 2 28 3.2% 5.3% 1.7% 3.2% Reformulated 204 29 47 280
1 RONMON Regular Midgrade Premium Total Conventional 451 43 68 562 66.6% 56.6% 58.1% 64.6% Oxygenated 22 4 2 28 3.2% 5.3% 1.7% 3.2% Reformulated 204 29 47 280 30.1% 38.2% 40.2% 32.2% Total 677 76 117 870
î› ›ƒfi‘ÿìäéëóø01
The Track & Field -- -- 1 10:00 11:30 14:00 15:00 15:00 16:30 jog 10:00 11:00 14:00 10:00 9:00 10:30 11:00 12:00 15:00 17:00 14:00 15:00 20:00 21:00 15:00 16:30 10:00 10:30 km 10:30 11:30 14:00 15:30 16:00
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Effect of Sympathetic and parasympathetic agents on cholesterol metabolism in mice salivary glands. Eriko, NEZU and Haruo, NAKAMURA (Department of Ora
Effect of Sympathetic and parasympathetic agents on cholesterol metabolism in mice salivary glands. Eriko, NEZU and Haruo, NAKAMURA (Department of Oral Physiology, Hokkaido University School of Dentistry,
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00
9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 ポスターについて 1. ポスター 貼 付 用 の 展 示 ボードは 縦 180 横 90cm の 大 きさです 2. 演 題 名 発 表 者 名 所 属 を 明 記 したもの(20 70cm) をご 用 意 ください 実 際 使 用 できるスペースは 155
日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
untitled
POLYAMINE -P Ver.1.0 MM ver. 1.0MM POLYAMINE 1. 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504 (1983). 2) Ha.C. et
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
untitled
Bul.Natl.SalmonResourcesCenter,No.8,26 2 Table1.PrevalenceofMyxoboluskisutchiinandsalmonfrom thecolumbiariverbasinanditsvicinities. Prevalence (%) No.offish infected No.offish examined Dateofcapture Locality
2015壺溪塾表1表4_0105
KOKEI JUKU GUIDANCE FOR SUCCESS ? ? ! ?! Courses Guide 前 年 度 合 格 校 : 東 京 大 学 / 京 都 大 学 / 一 橋 大 学 / 東 京 工 業 大 学 / 大 阪 大 学 など 卒 塾 生 の 声 卒 塾 生 の 声 Courses Guide 前 年 度 合 格 校 : 九 州 大 学 / 東 京 工 業 大 学 / 大
研究成果報告書(基金分)
(1) 種類 程度 肥満細胞数の測定と組織でのサ RT-PCR FACS () (1) NMU-/- IgE NMU IgE -/-NMU -/-B IgE NMU -/-B6 IgE NMU NMU CTLMC BMMC IgE NMU CTLMC 13 1. Hayakawa J, Mizukawa Y, Kurata M, Shiohara T: A syringotropic variant
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
報告書
1 2 3 4 5 6 7 or 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 2.65 2.45 2.31 2.30 2.29 1.95 1.79 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 60 55 60 75 25 23 6064 65 60 1015
Mikio Yamamoto: Dynamical Measurement of the E-effect in Iron-Cobalt Alloys. The AE-effect (change in Young's modulus of elasticity with magnetization
Mikio Yamamoto: Dynamical Measurement of the E-effect in Iron-Cobalt Alloys. The AE-effect (change in Young's modulus of elasticity with magnetization) in the annealed state of iron-cobalt alloys has been
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
56 pp , 2005 * ******* *** ** CA CAMA
Title 成人知的障害者の加齢に伴う外観的変化に関する研究 : 知的障害者用外観的老化微候測定法を用いた検討 Author(s) 春日井, 宏彰 ; 菅野, 敦 ; 橋本, 創一 ; 桜井, 和典 ; 片瀬, Citation 東京学芸大学紀要. 第 1 部門, 教育科学, 56: 415-425 Issue Date 2005-03-00 URL http://hdl.handle.net/2309/2097
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
CAS NC(CH 2 ) 4 CN 1,4- C 6 H 8 N c.c d = Pa
1 200117 21512 CAS 111693 110 NC(CH 2 ) 4 CN 1,4- C 6 H 8 N 2 108.14 1 99 2-1. 2 1 295 159 c.c. 550 3 1.7-4.9 20 d 0.965 4 3.73 = 1 0.3 Pa 0.002 mmhg20 2 log Pow-0.32 m/z 41, 1.0 68 0.54 54 0.43 4 Koc9-16
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug, Table 1 Incidence of changes in serotype of Pseudomonas aeruginosa isolates induced by anti-pseudomonal drugs Number of isolates
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
技術研究報告第２６号
1) 2) 3) 250Hz 500Hz RESEARCH ON THE PHYSICAL VOLUME OF THE DYNAMIC VIBRATION RESPONSE AND THE REDUCTION OF THE FLOOR IMPACT SOUND LEVEL IN FLOORS OF RESIDENTIAL HOUSING Hideo WATANABE *1 This study was
THE JAPANESE JOURNAL OF ANTIBIOTICS XXII-4 Aug. viable cell number was counted, the number decreased remarkably, then increasedrapidly number as the c
THE JAPANESE JOURNAL OF ANTIBIOTICS XXII-4 Aug. viable cell number was counted, the number decreased remarkably, then increasedrapidly number as the control. to the same (2) The some results were obtained
研究成果報告書
21 4 25 peroxynitrite angiotensin II ETA MEK/ERK pathway endothelin-1 EDHF (EDHF) EDHF EDHF EDHF 2 [phosphodiesterase 3 (PDE3) cilostazol metformin thromboxane A2 ozagrel eicosapentaenoic acid (EPA) angiotensin
Key words: elderly patients, neutrophil, chemiluminescence, LPS, TNF-a Table 1 Whole blood chemiluminescence Table 2 Neutrophil chemiluminescence Fig. 1 The average time course for non-opsonized zymosan-induced
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
untitled
FK506 FK506 2005 17 4 1 1,2) 1 1943 18 12 1944 9 11 1946 4 2 11 J. W. 1948 26 2 1949 11 19511954 E-mail: michio.yamashita@astellas.com 2013 3 141 1956 4 1 10 1 1961 10 NRDC C CC CC CC CC CCNa 1962 7-7ACA